FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2071625393> ?p ?o ?g. }

• W2071625393 endingPage "504" @default.
• W2071625393 startingPage "496" @default.
• W2071625393 abstract "Abstract On the basis of large cardiovascular clinical trials of lipid-lowering agents that showed a considerable decrease in the incidence of primary melanomas in the active agent arm, we have carried out a randomized, double-blind clinical trial examining the impact of lovastatin on various biomarkers of melanoma pathogenesis. Subjects with at least two clinically atypical nevi were randomized to receive oral lovastatin or placebo for a 6-month period. Clinical, histopathologic, and molecular biomarkers were evaluated for change in the two groups. Eighty subjects were randomized, evaluable, and included in the analyses. Lovastatin showed no benefit in comparison with placebo in the primary endpoint of decreasing the level of histopathologic atypia, nor in any of the secondary endpoints of decreasing clinical atypia, impact on nevus number, nor in showing significant changes in any of the molecular biomarkers. There were no significant differences in adverse event profiles for lovastatin compared with placebo. The lovastatin arm did show a significant and considerable decrease in total serum cholesterol and serum low-density lipoprotein (LDL) levels compared with placebo, an expected result. This finding bolsters confidence in subject compliance. Given the results of this trial, it is concluded that if lovastatin were to lower the incidence of melanoma, it would appear not to be doing so by reversing atypia of precursor atypical nevi over the 6-month time frame studied. Further research into the pathogenesis of melanoma and in other potential chemopreventive agents is needed. Cancer Prev Res; 7(5); 496–504. ©2014 AACR." @default.
• W2071625393 created "2016-06-24" @default.
• W2071625393 creator A5003508918 @default.
• W2071625393 creator A5009729746 @default.
• W2071625393 creator A5019815608 @default.
• W2071625393 creator A5021981756 @default.
• W2071625393 creator A5036941849 @default.
• W2071625393 creator A5051982352 @default.
• W2071625393 creator A5057233825 @default.
• W2071625393 creator A5058120847 @default.
• W2071625393 creator A5059656218 @default.
• W2071625393 creator A5060872059 @default.
• W2071625393 creator A5080451117 @default.
• W2071625393 creator A5080636708 @default.
• W2071625393 creator A5082067229 @default.
• W2071625393 creator A5082537748 @default.
• W2071625393 date "2014-05-01" @default.
• W2071625393 modified "2023-10-09" @default.
• W2071625393 title "A Randomized, Double-Blind, Placebo-Controlled Phase II Clinical Trial of Lovastatin for Various Endpoints of Melanoma Pathobiology" @default.
• W2071625393 cites W1490394333 @default.
• W2071625393 cites W1527721103 @default.
• W2071625393 cites W1970258245 @default.
• W2071625393 cites W1974151981 @default.
• W2071625393 cites W1985720030 @default.
• W2071625393 cites W1992125460 @default.
• W2071625393 cites W1994571309 @default.
• W2071625393 cites W1995933366 @default.
• W2071625393 cites W2015970158 @default.
• W2071625393 cites W2033165805 @default.
• W2071625393 cites W2041241587 @default.
• W2071625393 cites W2041951916 @default.
• W2071625393 cites W2047366788 @default.
• W2071625393 cites W2051712175 @default.
• W2071625393 cites W2055289413 @default.
• W2071625393 cites W2058134455 @default.
• W2071625393 cites W2087539121 @default.
• W2071625393 cites W2088055822 @default.
• W2071625393 cites W2097965253 @default.
• W2071625393 cites W2122507575 @default.
• W2071625393 cites W2158676766 @default.
• W2071625393 cites W2328529137 @default.
• W2071625393 cites W2404528336 @default.
• W2071625393 cites W3140388327 @default.
• W2071625393 cites W4212916723 @default.
• W2071625393 cites W4250286899 @default.
• W2071625393 cites W4362223089 @default.
• W2071625393 cites W4375932018 @default.
• W2071625393 doi "https://doi.org/10.1158/1940-6207.capr-13-0189" @default.
• W2071625393 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4208700" @default.
• W2071625393 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24614012" @default.
• W2071625393 hasPublicationYear "2014" @default.
• W2071625393 type Work @default.
• W2071625393 sameAs 2071625393 @default.
• W2071625393 citedByCount "22" @default.
• W2071625393 countsByYear W20716253932015 @default.
• W2071625393 countsByYear W20716253932016 @default.
• W2071625393 countsByYear W20716253932017 @default.
• W2071625393 countsByYear W20716253932018 @default.
• W2071625393 countsByYear W20716253932020 @default.
• W2071625393 countsByYear W20716253932021 @default.
• W2071625393 countsByYear W20716253932022 @default.
• W2071625393 countsByYear W20716253932023 @default.
• W2071625393 crossrefType "journal-article" @default.
• W2071625393 hasAuthorship W2071625393A5003508918 @default.
• W2071625393 hasAuthorship W2071625393A5009729746 @default.
• W2071625393 hasAuthorship W2071625393A5019815608 @default.
• W2071625393 hasAuthorship W2071625393A5021981756 @default.
• W2071625393 hasAuthorship W2071625393A5036941849 @default.
• W2071625393 hasAuthorship W2071625393A5051982352 @default.
• W2071625393 hasAuthorship W2071625393A5057233825 @default.
• W2071625393 hasAuthorship W2071625393A5058120847 @default.
• W2071625393 hasAuthorship W2071625393A5059656218 @default.
• W2071625393 hasAuthorship W2071625393A5060872059 @default.
• W2071625393 hasAuthorship W2071625393A5080451117 @default.
• W2071625393 hasAuthorship W2071625393A5080636708 @default.
• W2071625393 hasAuthorship W2071625393A5082067229 @default.
• W2071625393 hasAuthorship W2071625393A5082537748 @default.
• W2071625393 hasBestOaLocation W20716253931 @default.
• W2071625393 hasConcept C126322002 @default.
• W2071625393 hasConcept C141071460 @default.
• W2071625393 hasConcept C142724271 @default.
• W2071625393 hasConcept C143998085 @default.
• W2071625393 hasConcept C168563851 @default.
• W2071625393 hasConcept C197934379 @default.
• W2071625393 hasConcept C203092338 @default.
• W2071625393 hasConcept C204787440 @default.
• W2071625393 hasConcept C27081682 @default.
• W2071625393 hasConcept C2777658100 @default.
• W2071625393 hasConcept C2778163477 @default.
• W2071625393 hasConcept C2780940807 @default.
• W2071625393 hasConcept C2781283455 @default.
• W2071625393 hasConcept C502942594 @default.
• W2071625393 hasConcept C535046627 @default.
• W2071625393 hasConcept C71924100 @default.
• W2071625393 hasConcept C90924648 @default.
• W2071625393 hasConceptScore W2071625393C126322002 @default.
• W2071625393 hasConceptScore W2071625393C141071460 @default.
• W2071625393 hasConceptScore W2071625393C142724271 @default.

• next